TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06727513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A double-operator technique for GlideScope intubation
Description: A double-operator technique where the senior resident will insert the GlideScope until visualizing an optimal glottic view, then the attending physician will take over the GlideScope keeping it in the same fixed position, while the resident performs the endotracheal intubation using an angulated stylet.
Study: NCT06745258

Intervention type: OTHER
Intervention: External Facilitation
Description: Multi-component facilitation strategy to address identified implementation needs
Study: NCT06741137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide combined with prone position ventilation
Description: inhaled nitric oxide combined with prone position ventilation
Study: NCT04983667

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zn-AA
Description: Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zn-AA
Description: Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
Study: NCT06451562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: a local anesthetic drug of the amino amide type

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: a local anesthetic drug of the amino amide type
Study: NCT05340933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice registration
Description: Voice registration
Study: NCT06017752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAC Teacher Module
Description: The STAC Teacher Module is a 30-minute presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies teachers can use to support students who act as defenders, and information about perceptions vs. facts about bullying.
Study: NCT05558098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Current standard of care for management of critically ill patients
Study: NCT05144802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute hypoxia
Description: Participants will be exposed to a 3-hour acute hypoxia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acute hypoxia
Description: Participants will be exposed to a 3-hour acute hypoxia
Study: NCT05538975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Treatment
Description: Pulmonary Rehabilitation Techniques
Study: NCT06762457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-501
Description: MT-501 Tablets
Study: NCT05538975

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy Treatment
Description: Pulmonary Rehabilitation Techniques
Study: NCT06762626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer according to endometrial receptivity analysis result
Description: Frozen embryo transfer will be arranged according to endometrial receptivity analysis result, which will be shown in the form of P+X hours
Study: NCT06764914

Intervention type: OTHER
Intervention: integrative and complementary medicine
Description: Treatment with integrative and complementary methods for both, inpatients and outpatients, includes conventional therapy, integrative methods and ordinal therapy/MBM, which are individually designed for each patient. Similar to a shedule, with therapy units from the following areas: hydrotherapy/thermotherapy, exercise therapy, physiotherapy, nutritional therapy and bodywork therapy, supplemented as required by phytotherapeutic and other therapies, such as acupuncture, neural therapy and cupping. After inpatient treatment, patients can receive up to 10 additional outpatient treatments at our TCM outpatient clinic. There is also a 10-week programme for day patients. This focuses on ordinal therapy to achieve sustainable, balanced lifestyle changes. This includes classic acupuncture and drainage techniques such as Gua Sha (connective tissue massage in TCM) or cupping, as well as neural therapy, electro-acupuncture and others. Daily medical visits and self-care advice are also included.
Study: NCT06765109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral tablet of NVL-655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alectinib
Description: Oral capsule of alectinib
Study: NCT06767085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine Topical
Description: lidocaine-prilocaine spray on the cervix and cervical canal 5-7 minutes prior to the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: saline spray on the cervix and cervical canal 5-7 minutes prior to the procedure
Study: NCT06765421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Intervention group activity involves three components:~1. Intervention group GPs will be provided with a long COVID 'toolkit'. The toolkit will be prepared by the study team in collaboration with expert clinicians and public and patient representatives as a resource for GPs to use in patient care.~2. GPs will attend an expert clinician / patient led long COVID educational session grounded in the findings of the toolkit.~3. Applying learnings to date, each GP will conduct case reviews of eight patients with long COVID attending their practice and provide patient care as appropriate.
Study: NCT06762756

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Messages on tobacco packaging labels
Description: The intervention was messages of the benefits of smoking cessation formatted as tobacco packaging labels with three conditions. Participants viewed the messages online. There were four messages in each condition. The intervention was informed by relevant patient and public groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages on tobacco packaging labels
Description: The intervention was messages of the benefits of smoking cessation formatted as tobacco packaging labels with three conditions. Participants viewed the messages online. There were four messages in each condition. The intervention was informed by relevant patient and public groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Messages on tobacco packaging labels
Description: The intervention was messages of the benefits of smoking cessation formatted as tobacco packaging labels with three conditions. Participants viewed the messages online. There were four messages in each condition. The intervention was informed by relevant patient and public groups.
Study: NCT05582135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg morphine sulfate
Description: The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25mg/kg esketamine
Description: The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate
Description: The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate
Description: The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
Study: NCT05596149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste without fluoride
Description: A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste with sodium fluoride
Description: A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste with sodium monofluorophosphate
Description: A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
Study: NCT06769412

Intervention type: DRUG
Intervention: aflibercept 2 mg
Description: No study-specific investigations for this descriptive observational study
Study: NCT06769581

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular Brachial Plexus Blocks
Description: Lateral sagittal technique infraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular Brachial Plexus Blocks
Description: Lateral sagittal technique infraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular Brachial Plexus Blocks
Description: Lateral sagittal technique infraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular Brachial Plexus Blocks
Description: Lateral sagittal technique infraclavicular brachial plexus block
Study: NCT06768580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Patients will receive one capsule of melatonin (5mg) orally the night before surgery at 9 pm, the night of the operation, and two nights after the surgical operation at 9 pm, also the patients will receive 10 ml bolus of saline intravenous (IV) over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) until the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients will receive a bolus (10 ml) of intravenous lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. Continuous infusion of 1.5 mg/kg/hr of intravenous lidocaine diluted with saline (20 ml/hr) will be administered until the end of the surgery, also will receive placebo capsule the night before surgery at 9 pm, the night of operation and two nights after the surgical operation at 9 pm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a bolus (10 ml) of saline over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) and placebo capsule the night before surgery at 9 pm, the night of the operation and two nights after the surgical operation at 9 pm.
Study: NCT06769568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia
Description: reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia
Study: NCT06768112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Vagus Nerve Stimulation
Description: Using non-invasive vagus nerve stimulation at the ear to stimulate the adrenergic and serum hormone pathways, activating the frontal lobe system, sensory-motor nervous system, and cerebellum, to investigate the effects and neural mechanisms of dynamic posture training and learning.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: balance training
Description: Participants will be asked to stand on a soft-platform and hit on blaze-pod LED within 60 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: Participants will be asked to stand on a soft-platform and hit on blaze-pod LED within 60 seconds.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mini-Mental State Examination
Description: The mini-mental state examination (MMSE) or Folstein test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination
Description: The mini-mental state examination (MMSE) or Folstein test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment.
Study: NCT05596149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste with amine fluoride
Description: A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
Study: NCT06768086

Intervention type: PROCEDURE
Intervention: Hysteroscopic myomectomy
Description: The hysteroscopic myomectomies were conducted during the follicular phase of the menstrual cycle. Throughout the surgical procedure, the intrauterine pressure was meticulously maintained at less than 80 mm Hg. Data on the duration of the surgical intervention, the volume of fluid administered, and the volume of fluid absorbed were collected. Complete resection was characterized as the total excision of the myoma. The determination of the completeness of myomectomy was made by the experienced surgeon during the surgical process. In instances where the resection was deemed incomplete, the decision to pursue a secondary surgical intervention was predicated on ultrasonographic evaluations, the symptomatic presentation of the patients, and, in certain circumstances, the findings from diagnostic hysteroscopy. Cases in which access to the uterine cavity was unfeasible were classified as failed procedures and were subsequently excluded from the study.

Intervention type: PROCEDURE
Intervention: Hysteroscopic myomectomy
Description: The hysteroscopic myomectomies were conducted during the follicular phase of the menstrual cycle. Throughout the surgical procedure, the intrauterine pressure was meticulously maintained at less than 80 mm Hg. Data on the duration of the surgical intervention, the volume of fluid administered, and the volume of fluid absorbed were collected. Complete resection was characterized as the total excision of the myoma. The determination of the completeness of myomectomy was made by the experienced surgeon during the surgical process. In instances where the resection was deemed incomplete, the decision to pursue a secondary surgical intervention was predicated on ultrasonographic evaluations, the symptomatic presentation of the patients, and, in certain circumstances, the findings from diagnostic hysteroscopy. Cases in which access to the uterine cavity was unfeasible were classified as failed procedures and were subsequently excluded from the study.
Study: NCT06769035

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa, amaranth seed and ginger
Description: Sachet with 20gr of cocoa, 10g of amaranth seed and 1g of ginger, one dose per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amaranth seed
Description: Sachet with 10g of amaranth seed one dose per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa
Description: Sachet with 20gr of cocoa one dose per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachet with coloring and flavoring, one dose per day for 12 weeks one dose per day for 12 weeks
Study: NCT06768138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of Alteplase
Description: Patients enrolled in the experimental arm will receive intra-arterial thrombolysis with Alteplase. The dose of Intra-arterial Alteplase is 0.225 mg/kg body weight with a maximal dose of 20 mg
Study: NCT06768424

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided biofilm therapy
Description: Use of Airflow Plus powder subgingivally on teeth with deep periodeontal pockets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided biofilm therapy
Description: Use of Airflow Plus powder subgingivally on teeth with deep periodeontal pockets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Pack Platelet Rich Fibrin chops into the intrabony periodontla defect

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Pack Platelet Rich Fibrin chops into the intrabony periodontla defect

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgical Technique
Description: Periodontal intrabony defect is treated by minimally invasive surgical intervention
Study: NCT06768697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KFD1(0µg )
Description: SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(0µg + 80µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KFD1(20µg)
Description: SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(20µg + 80µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KFD1(40µg)
Description: SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(40µg + 80µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KFD1(80µg)
Description: SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(80µg + 80µg)
Study: NCT06769360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PMI-targeted PSV setting
Description: The pressure support is adjusted according to PMI between 0 and 2 cmH2O. After application of PSV mode in mechanically ventilated patients, the initial PS level was first set based on respiratory rate (RR) \<35 beats/min and 6-8 ml/Kg tidal volume (Vt) per predict body weight (PBW), and then modified according to PMI at a frequency of twice a day (morning and afternoon bedside rounds)# 1) Perform three end- inspiratory occlusions, with at least 1 minute between each measurement, and calculate the mean PMI. 2) Determine whether the PMI is within the target range (0≤PMI≤2cmH2O). 3) If the PMI is not within the target range, adjust the PS level up or down by 1-3 cmH2O and balance for 3-5 minutes. 4) Repeat the above steps until PMI reaches the target. 5) Additional: During PS adjustment, if Vt≤4ml/Kg, respiratory acidosis, respiratory distress, Vt≥8ml/Kg, respiratory alkalosis occurs, return to the safe PS level before adjustment and optimize other treatments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VT/RR-targeted PSV setting
Description: Standard of care: the pressure support is adjusted to obtain a VT between 6 and 8 ml/kg PBW and RR between 20 and 35 breaths/min.
Study: NCT06767865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online support programe
Description: Individuals in the experimental group received online training and were subsequently provided with continuous follow-up, counseling, motivation and informative message support for three months. In addition, patients were given a target board containing a daily diabetes management program and were asked to use it for three months.
Study: NCT06767722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention and self-monitoring of blood glucose
Description: The intervention will consist of a lifestyle intervention that comprises advice on diet, exercise, weight management, and self-monitoring of blood glucose (SMBG) with feedback from healthcare professionals on results and insulin treatment if indicated.
Study: NCT06765655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Injection
Description: point-of-care glucose monitoring via fingerstick perioperatively

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: glucose testing
Description: POCT glucose testing via fingerstick
Study: NCT04662866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
Description: Comparison of 4 different antihyperglycemic drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
Description: Comparison of 4 different antihyperglycemic drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
Description: Comparison of 4 different antihyperglycemic drugs
Study: NCT06769490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Participants will receive treatment in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Participants will receive treatment in tablet form
Study: NCT04662866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
Description: Comparison of 4 different antihyperglycemic drugs